JP2010521458A5 - - Google Patents

Download PDF

Info

Publication number
JP2010521458A5
JP2010521458A5 JP2009553600A JP2009553600A JP2010521458A5 JP 2010521458 A5 JP2010521458 A5 JP 2010521458A5 JP 2009553600 A JP2009553600 A JP 2009553600A JP 2009553600 A JP2009553600 A JP 2009553600A JP 2010521458 A5 JP2010521458 A5 JP 2010521458A5
Authority
JP
Japan
Prior art keywords
group
trifluoromethyl
ylamino
pyridin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009553600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521458A (ja
JP5569956B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003205 external-priority patent/WO2008115369A2/en
Publication of JP2010521458A publication Critical patent/JP2010521458A/ja
Publication of JP2010521458A5 publication Critical patent/JP2010521458A5/ja
Application granted granted Critical
Publication of JP5569956B2 publication Critical patent/JP5569956B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009553600A 2007-03-16 2008-03-10 接着斑キナーゼのインヒビター Expired - Fee Related JP5569956B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89537907P 2007-03-16 2007-03-16
US60/895,379 2007-03-16
US94663707P 2007-06-27 2007-06-27
US60/946,637 2007-06-27
US3002508P 2008-02-20 2008-02-20
US61/030,025 2008-02-20
PCT/US2008/003205 WO2008115369A2 (en) 2007-03-16 2008-03-10 Inhibitors of focal adhesion kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014104005A Division JP2014148542A (ja) 2007-03-16 2014-05-20 接着斑キナーゼのインヒビター

Publications (3)

Publication Number Publication Date
JP2010521458A JP2010521458A (ja) 2010-06-24
JP2010521458A5 true JP2010521458A5 (enExample) 2011-05-06
JP5569956B2 JP5569956B2 (ja) 2014-08-13

Family

ID=39628767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009553600A Expired - Fee Related JP5569956B2 (ja) 2007-03-16 2008-03-10 接着斑キナーゼのインヒビター
JP2014104005A Pending JP2014148542A (ja) 2007-03-16 2014-05-20 接着斑キナーゼのインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014104005A Pending JP2014148542A (ja) 2007-03-16 2014-05-20 接着斑キナーゼのインヒビター

Country Status (10)

Country Link
US (2) US8501763B2 (enExample)
EP (2) EP2134689B1 (enExample)
JP (2) JP5569956B2 (enExample)
CN (2) CN103588704B (enExample)
CA (1) CA2681015C (enExample)
DK (1) DK2134689T3 (enExample)
ES (1) ES2485040T3 (enExample)
PL (1) PL2134689T3 (enExample)
TW (2) TWI536991B (enExample)
WO (1) WO2008115369A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134689B1 (en) 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
KR20100067046A (ko) * 2008-12-10 2010-06-18 동화약품주식회사 신규한 ２，６―위치에 치환된 ３―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
EP2464642A4 (en) * 2009-08-12 2013-01-09 Poniard Pharmaceuticals Inc PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
CA2803004A1 (en) * 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Oral formulations of kinase inhibitors
CN103168037A (zh) * 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 激酶抑制剂的合成和用途
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
JP6027230B2 (ja) 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
RU2015147601A (ru) * 2013-05-01 2017-06-05 Ф. Хоффманн-Ля Рош Аг С-связанные гетероциклоалкилзамещенные пиримидины и их применения
WO2015035199A1 (en) * 2013-09-06 2015-03-12 Mayo Foundation For Medical Education And Research Neem compositions used for the treatment of cancer
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
CA3002558A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
SG11201803242TA (en) 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
WO2017089985A1 (en) * 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
DK3582776T3 (da) 2017-02-14 2024-01-08 Effector Therapeutics Inc Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CA3109617A1 (en) 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
EP3870178A4 (en) 2018-10-24 2022-08-03 Effector Therapeutics Inc. Crystalline forms of mnk inhibitors
CN110724137B (zh) * 2019-11-13 2021-03-30 广东工业大学 一种噻吩类衍生物及其制备方法与应用
CN111233834B (zh) * 2020-03-09 2021-08-31 北京师范大学 一类靶向fak的化合物和其标记物、及它们的制备方法和应用
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
GB202113079D0 (en) * 2021-09-14 2021-10-27 Ucl Business Ltd New therapy
WO2023218245A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof
CN121335887A (zh) * 2023-06-08 2026-01-13 希格生科（深圳）有限公司 含氮芳环化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU63802A (sh) * 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP2134689B1 (en) 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak

Similar Documents

Publication Publication Date Title
JP5569956B2 (ja) 接着斑キナーゼのインヒビター
RU2615130C2 (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
EP3087070B1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP7175888B2 (ja) 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
AU2014367283B2 (en) Maleimide derivatives as modulators of WNT pathway
BRPI0716918A2 (pt) Composto, composição farmacêutica, composição farmacêutica embalada, método de tratar um paciente que apresente uma doença responsiva à inibição da atividade btk, método de tratar um paciente que apresente uma doença escolhida dentre câncer, doenças autoimunes, reações inflamatórias agudas e transtornos alérgicos, método de aumentar a sensibilidade de células cancerosas à quimioterapia, método de reduzir o erro de medicação e melhorar o cumprimento terapêutico de um paciente sendo tratado para uma doença responsiva à inibição da atividade btk, método de inibir a hidrólise de atp, método para determinar a presença de btk em uma amostra, método de inibir a atividade de células-b
CN101072755A (zh) Hedgehog信号转导的吡啶基抑制剂
WO2008150446A1 (en) Inhibitors of protein kinases
CN103539784A (zh) 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015187094A1 (en) Phthalimide derivatives as modulators of wnt pathway
US12059420B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
HK1141521A (en) Inhibitors of focal adhesion kinase
HK1194380B (en) Inhibitors of focal adhesion kinase
HK1194380A (en) Inhibitors of focal adhesion kinase
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
CN119816492A (zh) Trpv2通道阻断剂及其用途
TW202237082A (zh) 安諾特明６（Ａｎｏｃｔａｍｉｎ ６）之抑制劑及其用途